Emerging Markets-China

The Ultimate Analysis of Pharmaceutical Markets in China

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Based on client demand, China is the first country to receive our attention. With these reports, you will be able to:

• More accurately assess your commercial opportunity for Western brands in China
• Understand the physician treatment patterns and drivers of choice in key urban areas based on primary research
• Gain a clear perspective from our 5-year, drug-level market forecast, which is broken out by multinational sales versus Chinese-based companies

Each China report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology, and changing physicians’ practices. Key elements of each report include:

• Accurate sizing of the patient population with access to Western medicine
• Projections for future patient populations based on trends in lifestyle, urbanization, and economic status
• Current treatment patterns and drivers of choice
• Physician-defined unmet needs in diagnosing and treating the disease
• Disease-specific pricing and reimbursement environment
• Key drivers of market growth

Methodology for Generating Epidemiology Estimates

Our most recent Emerging Markets reports:

Renal Cell Carcinoma in China

Type 2 Diabetes in China

Gastric Cancer in China

Rheumatoid Arthritis in China

Liver Cancer in China

Download our Emerging Markets-China brochure

View 2008 Emerging Markets report titles